FDA Approves Nivolumab With Chemotherapy for Gastric and Esophageal Cancer

The FDA has granted approval to nivolumab (Opdivo®, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the initial treatment of patients with advanced/metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. "Standard first-line chemotherapy options for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer result in poor overall su...

New Cetuximab Dosing Guidelines Approved for Colorectal Cancer and Head and Neck Cancer

The FDA has approved a new dosing regimen of 500 mg/m2 cetuximab (Erbitux®, Eli Lilly) for patients with KRAS wild-type epidermal growth factor receptor (EGFR)–expressing metastatic colorectal cancer (CRC) and patients with head and neck squamous cell carcinoma (HNSCC). This biweekly dosage regimen serves as an alternative to the existing weekly dosage regimen of cetuximab, whether on its own or combined with chemotherapy, and should be administered as a single 120-minute intravenous infusion ev...

Isatuximab-Irfc Combination Approved for Multiple Myeloma

The FDA has approved isatuximab-irfc (Sarclisa®, Sanofi) in combination with carfilzomib and dexamethasone (Kd), for adult patients with relapsed or refractory multiple myeloma who have previously received one to three lines of therapy. "Treatment of relapsed/refractory multiple myeloma (RRMM) has greatly improved, yet relapse is inevitable and additional effective treatments are needed," wrote Philippe Moreau, MD, Head of the Hematology Department at the University Hospital of Nantes in France,...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.